Inscripta Stock

Inscripta is a gene editing technology company.

Sign up today and learn more about Inscripta Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.



Notable Investors



Boulder CO, US

Total Funding


About Inscripta Stock

Inscripta is a gene-editing technology company that puts researchers in control by making it easy for them to get all they need for cutting-edge, forward cell-engineering. These tools include a family of CRISPR enzymes (called MADzymes), custom nucleases for researchers and commercial partners, and a full suite of gene-editing tools (instruments, reagents, and software) that will significantly increase the speed and efficiency of multiplexed, precision gene editing. By removing the barriers to forward cell engineering and gene-editing research, Inscripta will usher in a new era of advances to revolutionize how we feed, fuel, and heal humanity. Inscripta is led by several genomic technology veterans including CEO Kevin Ness, who co-founded QuantaLife and 10x Genomics, and John Stuelpnagel, the chairman of the company's board, who was co-founder and first CEO of Illumina and chairman of 10x Genomics. Inscripta is headquartered in Boulder, Colo.; has offices in Pleasanton, Calif.; and is backed by Venrock, MLS Capital, NanoDimension, Foresite, Paladin Capital Group, and Mérieux Développement.


Funding History

April 2016$6.0M
February 2017$23.1M
February 2018$55.5M
January 2019$50.0M
November 2019$175M
March 2021$150M


General Counsel

Dianna DeVore

VP Finance

Eric Warnecke

CSO & Founder

Ryan T Gill

VP Product Development

Michael Graige

VP Software

Todd Rubano

VP Biology

Paul Hardenbol

Executive Director of Data Science

Richard Fox


Kevin Ness

CTO, VP R&D, Co Founder

Tanya Lipscomb

VP Engineering

Don Masquelier


synbiobeta - Dec, 3 2021

Scientist, Inscripta, Pleasanton, CA

synbiobeta - Sep, 15 2021

Account Executive, Inscripta, US

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: